Oral Activated Charcoal's Role in Reducing Urea, Creatinine, and Phosphorous in Chronic Kidney Disease
This phase 2 study aims to assess how oral activated charcoal affects blood levels of urea, creatinine, and phosphorous in patients with chronic kidney disease.
Activated charcoal
+ Dry seeds
Treatment Study
Summary
Study start date: August 1, 2020
Actual date on which the first participant was enrolled.Chronic Kidney Disease (CKD) is a growing health concern worldwide. This condition often leads to complications like heart diseases, malnutrition, and anemia. The build-up of toxins, such as indoxyl sulfate and p-cresyl sulfate, worsens the condition and increases the risk of heart diseases. Many patients refuse to start chronic hemodialysis, a common treatment for CKD. This study focuses on finding alternative treatments that can lower the levels of these toxins, potentially slowing down the progression of CKD. One such alternative is oral activated charcoal. The study also explores the use of dry seeds, like lentils, as a potential absorbent for these toxins. In this trial, participants with CKD will be given a daily dose of 30gm of oral activated charcoal. The study aims to measure the levels of blood urea, creatinine, and phosphorous in these patients before and after the treatment. This will help assess the effectiveness of oral activated charcoal in reducing these toxins. The study will also compare the effects of oral activated charcoal with dry seeds as an absorbent for uremic toxins. The potential benefits include a slower progression of CKD and improved overall health for patients.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.90 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 70 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Criteria
Inclusion Criteria: Patients with CKD stages iii and iv Patients with age more than 18 years old Exclusion Criteria: Patients on regular hemodialysis Patients with age less than 18 years old
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.2 intervention groups are designated in this study
This study does not include a placebo group
Treatment Groups
Group I
Group II
Study Objectives
Primary Objectives
Secondary Objectives